




FIG.1




FIG.2




FIG.3




FIG.4A




FIG.4B




FIG. 5A





FIG.5B






FIG.7




FIG.8A




FIG.8B




FIG. 9A




FIG.9B




FIG.10A




FIG.10B




FIG.10C




FIG.11




FIG.12A




FIG.12B




FIG. 13A




FIG.13B







FIG.14A








Cont. On FIG.16-2

FIG.16-1






FIG.17

nLC-MS assay	TIC/UV Peaks	Proposed Identity	Relative Abundance
nSEC-MS	HMW1	NISTmAb dimer	0.1%
	HMW2	NISTmAb dimer	1.3%
	Main	NISTmAb	98.2%
	LMW1	NISTmAb-Fab [LC+HC(1-223/227)]	
	LMW2	Fab [LC+HC(1-222~228)]	0.4%
	a	Fab [LC+HC(1-224)]	0.02%
	b	NISTmAb-Fab [LC+HC(1-227)]	0.05%
	c	Fab [LC+HC(1-223)] & Fab [LC+HC(1-225)]	0.07%
	d	NISTmAb-Fab [LC+HC(1-223)]	0.04%
	e	Fab [LC+HC(1-227)] & Fab [LC+HC(1-228)]	0.06%
	f	Fab [LC+HC(1-222)]	0.13%
nIEX-MS	Acidic 1	NISTmAb+CML (carboxymethyl); NISTmAb+G3FS	5.74%
	Acidic 2	NISTmAb + deamidation NISTmAb + NeuGc	6.43%
	Main	NISTmAb	73.82%
	Basic 1	NISTmAb + 1 unremoved C-term Lys	9.12%
	Basic 2	NISTmAb + 1 unconverted N-term Q;	4.51%
		NISTmAb + 2 unremoved C-term Lys	

FIG.18